Sign in

Omari Baruti

Research Analyst at Goldman Sachs Group Inc.

Omari Baruti is a Research Analyst at Goldman Sachs, specializing in healthcare and biotechnology sector equity research with a focus on innovative therapeutics. He has participated on earnings calls and covered companies such as Passage Bio, Syndax Pharmaceuticals, Jazz Pharmaceuticals, and Altimmune, providing analytical insights that inform institutional investment decisions. Baruti joined the Goldman Sachs research team after prior roles in the industry, building a career centered on rigorous financial analysis of drug developers and biotechnology trends. He holds industry-standard professional credentials, including FINRA registration and relevant securities licenses, establishing his credibility in delivering in-depth research for major client portfolios.

Omari Baruti's questions to Passage BIO (PASG) leadership

Question · Q4 2022

Omari Baruti from Goldman Sachs asked about the specific outputs from the early infantile high-dose GM1 cohort needed to advance to registrational studies and whether there is any visibility on the potential registrational endpoint.

Answer

CEO Will Chou stated that the key outputs they are looking for are durable decreases in GM1 ganglioside levels and improvements in patient development. Chief Medical Officer Mark Forman added that the specific registrational endpoints will be defined following ongoing discussions with health authorities.

Ask follow-up questions

Question · Q4 2022

Omari Baruti from Goldman Sachs asked about the specific outputs Passage Bio is looking for in the early infantile high-dose GM1 cohort to justify pursuing registrational studies and whether there is any visibility on the potential registrational endpoint for GM1.

Answer

CEO Will Chou stated they are looking for two key outputs: durable decreases in GM1 ganglioside levels and measurable improvement in patient development. CMO Mark Forman added that the specific registrational endpoints will be defined following ongoing discussions with regulatory health authorities.

Ask follow-up questions

Get Instant Answers from SEC Filings & Earnings Calls

Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.

Search across 8,000+ companies
Access millions of SEC filings & transcripts
Get answers cited to the source
Try Fintool for Free

Trusted by leading investment firms and analysts